364 related articles for article (PubMed ID: 20237460)
1. Gender-specific association of galanin polymorphisms with HPA-axis dysregulation, symptom severity, and antidepressant treatment response.
Unschuld PG; Ising M; Roeske D; Erhardt A; Specht M; Kloiber S; Uhr M; Müller-Myhsok B; Holsboer F; Binder EB
Neuropsychopharmacology; 2010 Jun; 35(7):1583-92. PubMed ID: 20237460
[TBL] [Abstract][Full Text] [Related]
2. HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients.
Binder EB; Künzel HE; Nickel T; Kern N; Pfennig A; Majer M; Uhr M; Ising M; Holsboer F
Psychoneuroendocrinology; 2009 Jan; 34(1):99-109. PubMed ID: 18829172
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms in the galanin gene are associated with symptom-severity in female patients suffering from panic disorder.
Unschuld PG; Ising M; Erhardt A; Lucae S; Kohli M; Kloiber S; Salyakina D; Thoeringer CK; Kern N; Lieb R; Uhr M; Binder EB; Müller-Myhsok B; Holsboer F; Keck ME
J Affect Disord; 2008 Jan; 105(1-3):177-84. PubMed ID: 17573119
[TBL] [Abstract][Full Text] [Related]
4. Association analysis for corticotropin releasing hormone polymorphisms with the risk of major depressive disorder and the response to antidepressants.
Chang HS; Won E; Lee HY; Ham BJ; Lee MS
Behav Brain Res; 2015 Oct; 292():116-24. PubMed ID: 26055202
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal neuroendocrine changes assessed by dexamethasone/CRH and growth hormone releasing hormone tests in psychotic depression.
Owashi T; Otsubo T; Oshima A; Nakagome K; Higuchi T; Kamijima K
Psychoneuroendocrinology; 2008 Feb; 33(2):152-61. PubMed ID: 18068306
[TBL] [Abstract][Full Text] [Related]
6. Polymorphisms in the BDNF and BDNFOS genes are associated with hypothalamus-pituitary axis regulation in major depression.
Hennings JM; Kohli MA; Uhr M; Holsboer F; Ising M; Lucae S
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Dec; 95():109686. PubMed ID: 31295515
[TBL] [Abstract][Full Text] [Related]
7. Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.
Papiol S; Arias B; Gastó C; Gutiérrez B; Catalán R; Fañanás L
J Affect Disord; 2007 Dec; 104(1-3):83-90. PubMed ID: 17467808
[TBL] [Abstract][Full Text] [Related]
8. The influence of Hatha yoga as an add-on treatment in major depression on hypothalamic-pituitary-adrenal-axis activity: a randomized trial.
Sarubin N; Nothdurfter C; Schüle C; Lieb M; Uhr M; Born C; Zimmermannc R; Bühner M; Konopka K; Rupprecht R; Baghai TC
J Psychiatr Res; 2014 Jun; 53():76-83. PubMed ID: 24655586
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and nonpharmacological factors influencing hypothalamic-pituitary-adrenocortical axis reactivity in acutely depressed psychiatric in-patients, measured by the Dex-CRH test.
Künzel HE; Binder EB; Nickel T; Ising M; Fuchs B; Majer M; Pfennig A; Ernst G; Kern N; Schmid DA; Uhr M; Holsboer F; Modell S
Neuropsychopharmacology; 2003 Dec; 28(12):2169-78. PubMed ID: 12931142
[TBL] [Abstract][Full Text] [Related]
10. FKBP5 polymorphisms and hypothalamic-pituitary-adrenal axis negative feedback in major depression and obsessive-compulsive disorder.
Ferrer A; Costas J; Labad J; Salvat-Pujol N; Segalàs C; Urretavizcaya M; Real E; de Arriba-Arnau A; Alonso P; Crespo JM; Barrachina M; Soriano-Mas C; Carracedo Á; Menchón JM; Soria V
J Psychiatr Res; 2018 Sep; 104():227-234. PubMed ID: 30107269
[TBL] [Abstract][Full Text] [Related]
11. PCLO rs2522833 modulates HPA system response to antidepressant treatment in major depressive disorder.
Schuhmacher A; Mössner R; Höfels S; Pfeiffer U; Guttenthaler V; Wagner M; Schwab SG; Maier W; Zobel A
Int J Neuropsychopharmacol; 2011 Mar; 14(2):237-45. PubMed ID: 20701824
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a Multicenter Study.
Kunugi H; Ida I; Owashi T; Kimura M; Inoue Y; Nakagawa S; Yabana T; Urushibara T; Kanai R; Aihara M; Yuuki N; Otsubo T; Oshima A; Kudo K; Inoue T; Kitaichi Y; Shirakawa O; Isogawa K; Nagayama H; Kamijima K; Nanko S; Kanba S; Higuchi T; Mikuni M
Neuropsychopharmacology; 2006 Jan; 31(1):212-20. PubMed ID: 16123748
[TBL] [Abstract][Full Text] [Related]
13. Hypothalamic-pituitary-adrenocortical axis dysregulation in patients with major depression is influenced by the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene.
Baghai TC; Schule C; Zwanzger P; Minov C; Zill P; Ella R; Eser D; Oezer S; Bondy B; Rupprecht R
Neurosci Lett; 2002 Aug; 328(3):299-303. PubMed ID: 12147330
[TBL] [Abstract][Full Text] [Related]
14. Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression.
Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E
Psychoneuroendocrinology; 2004 Oct; 29(9):1101-8. PubMed ID: 15219633
[TBL] [Abstract][Full Text] [Related]
15. [The neuroendocrinology of stress and the pathophysiology and therapy of depression and anxiety].
Ströhle A
Nervenarzt; 2003 Mar; 74(3):279-91; quiz 292. PubMed ID: 12627245
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms of the glucocorticoid receptor gene and major depression.
van Rossum EF; Binder EB; Majer M; Koper JW; Ising M; Modell S; Salyakina D; Lamberts SW; Holsboer F
Biol Psychiatry; 2006 Apr; 59(8):681-8. PubMed ID: 16580345
[TBL] [Abstract][Full Text] [Related]
17. Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.
Liu Z; Zhu F; Wang G; Xiao Z; Tang J; Liu W; Wang H; Liu H; Wang X; Wu Y; Cao Z; Li W
Neurosci Lett; 2007 Mar; 414(2):155-8. PubMed ID: 17258395
[TBL] [Abstract][Full Text] [Related]
18. Stress responsive neurohormones in depression and anxiety.
Ströhle A; Holsboer F
Pharmacopsychiatry; 2003 Nov; 36 Suppl 3():S207-14. PubMed ID: 14677081
[TBL] [Abstract][Full Text] [Related]
19. HPA axis dysfunction in unmedicated major depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural activity in prefrontal cortex and limbic/paralimbic regions.
Aihara M; Ida I; Yuuki N; Oshima A; Kumano H; Takahashi K; Fukuda M; Oriuchi N; Endo K; Matsuda H; Mikuni M
Psychiatry Res; 2007 Aug; 155(3):245-56. PubMed ID: 17587554
[TBL] [Abstract][Full Text] [Related]
20. Effects of escitalopram/quetiapine combination therapy versus escitalopram monotherapy on hypothalamic-pituitary-adrenal-axis activity in relation to antidepressant effectiveness.
Nothdurfter C; Schmotz C; Sarubin N; Baghai TC; Laenger A; Lieb M; Bondy B; Rupprecht R; Schüle C
J Psychiatr Res; 2014 May; 52():15-20. PubMed ID: 24513501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
